MIRA INFORM REPORT

 

 

Report Date :

01.11.2012

 

IDENTIFICATION DETAILS

 

Name :

PHARMA NOSTRA COMERCIAL LTDA

 

 

 

 

Registered Office :

Rua Aquidabã, 1144 - Lins De Vasconcelos 20720-294 - Rio De Janeiro/Rj

 

 

 

 

Country :

Brazil

 

 

 

 

Financials (as on) :

31.12.2010

 

 

 

 

Date of Incorporation :

28.10.1999

 

 

 

 

Legal Form :

Limited Liability Company

 

 

 

 

Line of Business :

Wholesale of Pharmaceuticals, Medical, Cosmetic and Chemical Products As Well As Reagents and Hemo-Derivatives.

 

 

 

 

No. of Employees :

Not Available

 

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 30th, 2012

 

Country Name

Previous Rating

(31.03.2011)

Current Rating

(30.06.2012)

Brazil

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

BRAZIL - ECONOMIC OVERVIEW

 

Characterized by large and well-developed agricultural, mining, manufacturing, and service sectors, Brazil's economy outweighs that of all other South American countries, and Brazil is expanding its presence in world markets. Since 2003, Brazil has steadily improved its macroeconomic stability, building up foreign reserves, and reducing its debt profile by shifting its debt burden toward real denominated and domestically held instruments. In 2008, Brazil became a net external creditor and two ratings agencies awarded investment grade status to its debt. After strong growth in 2007 and 2008, the onset of the global financial crisis hit Brazil in 2008. Brazil experienced two quarters of recession, as global demand for Brazil's commodity-based exports dwindled and external credit dried up. However, Brazil was one of the first emerging markets to begin a recovery. In 2010, consumer and investor confidence revived and GDP growth reached 7.5%, the highest growth rate in the past 25 years. Rising inflation led the authorities to take measures to cool the economy; these actions and the deteriorating international economic situation slowed growth to 2.7% for 2011 as a whole, though forecasts for 2012 growth are somewhat higher. Despite slower growth in 2011, Brazil overtook the United Kingdom as the world's seventh largest economy in terms of GDP. Urban unemployment is at the historic low of 4.7% (December 2011), and Brazil's traditionally high level of income equality has declined for each of the last 12 years. Brazil's high interest rates make it an attractive destination for foreign investors. Large capital inflows over the past several years have contributed to the appreciation of the currency, hurting the competitiveness of Brazilian manufacturing and leading the government to intervene in foreign exchanges markets and raise taxes on some foreign capital inflows. President Dilma ROUSSEFF has retained the previous administration's commitment to inflation targeting by the central bank, a floating exchange rate, and fiscal restraint.

Source : CIA


Company name

 

PHARMA NOSTRA COMERCIAL LTDA

 

 

ADDRESSES

 

MAIN ADDRESS:

RUA AQUIDABÃ, 1144 - LINS DE VASCONCELOS

ZIP CODE/CITY:

20720-294 - RIO DE JANEIRO/RJ

 

 

PHONE:

21 2141-1555

FAX:

21 2141-1555

E-MAIL:

thiago.silva@pharmanostra.com.br

WEB SITE:

www.pharmanostra.com.br

 

BRANCHES:

 

 

 

ADDRESS:

VIA PRIMÁRIA 5D - QUADRA 10 MÓDULO 01 S/Nº. DAIA

ZIP CODE/CITY:

75133-600 ANÁPOLIS/GO

PHONE:

62 3316-5226

CNPJ:

03.497.220/0002-41

 

 

ADDRESS:

RUA ESTÁCIO DE SÁ, 530 - JARDIM SANTA GENEBRA

ZIP CODE/CITY:

13080-010 CAMPINAS/SP

PHONE:

19 2101-4000

CNPJ:

03.497.220/0003-22

 

 

LEGAL DATA

 

MAIN ACTIVITIES:

 

WHOLESALE OF PHARMACEUTICALS, MEDICAL, COSMETIC AND CHEMICAL PRODUCTS AS WELL AS REAGENTS AND HEMO-DERIVATIVES.

 

LEGAL FORM:

LIMITED LIABILITY COMPANY

 

 

INCORPORATION DATE:

28/10/1999

REGISTER DATE:

11/09/1999

BALANCE SHEET FILING DATE:

31/12

TAX CONTRIBUTOR NUMBER(CNPJ):

03.497.220/0001-60

STATE REGISTER:

77.002.782

 

 

SHARE CAPITAL:

R$ 1.200.000,00

LAST REGISTER OF CAPITAL:

22/06/2007

 

 

 

BOARD OF DIRECTORS:

 

 

 

RAFAEL PADILHA PAPACEIT

MANAGER

IVAN JOSE MAROSTICA

MANAGER

 

 

AUTHORIZED USE OF SIGNATURE

 

THE MANAGERS ARE AUTHORIZED TO SIGN ON BEHALF OF THE COMPANY.

 

SHAREHOLDERS / PARTNERS:

 

 

 

FLAGRON EMPREENDIMENTOS E PARTICIPAÇÕES LTDA

100%

 

AFFILIATES / SUBSIDIARIES:

 

 

 

A SCAN THROUGH OUTSIDE SOURCES SHOWED THE SUBJECT AND/OR PARTNERS HAVE THE FOLLOWING UNCONFIRMED HOLDINGS:

 

 

SM EMPREENDIMENTOS FARMACÊUTICOS LTDA

 

VIA FARMA IMPORTADORA LTDA

 

TECABERABA PARTICIPAÇÕES LTDA

 

LEAL & MAROSTICA REPRESENTAÇÕES COMERCIAIS LTDA

 

 

 

COMPANY'S BACKGROUND

 

THE SUBJECT WAS ESTABLISHED ON OCTOBER 28, 1999 TO BE ENGAGED IN THE SAID LINE OF BUSINESS.

 

TRADE NAME: "PHARMA NOSTRA".

 

FURTHER DETAILS ARE SO FAR NOT KNOWN.

 

WHEN INTERVIEWED SOURCES AT THE SUBJECT STATED THAT ARE STILL WAITING FOR AUTHORIZATION FROM THE PRINCIPALS TO PROVIDE THE DATA NECESSARY TO COMPLETE THIS REPORT.

 

A REQUEST FOR FURTHER DATA HAS BEEN SENT TO THE COMPANY. PROVIDED THE DATA REQUESTED ARE RECEIVED FROM THE SUBJECT A COMPLEMENTARY REPORT WILL BE SENT TO YOUR ATTENTION.

 

THE DATA CONTAINED HEREIN WERE OBTAINED FROM OUTSIDE SOURCES, OUR DATABASE AND OFFICIAL. NO FURTHER DATA WAS AVAILABLE WITH SEVERAL SOURCES USUALLY INVESTIGATED.

 


 

PUBLIC RECORDS INFORMATION:

 

PROTESTS:

 

5  PROTESTS,TOTAL AMOUNT R$ 123.770,00

 

DETAILS OF LATEST PROTESTS:

 

NOTARY OFFICE:

DATE:

VALUE:

2º CARTÓRIO DE GO-ANÁPOLIS

06/08/2012

R$ 46.000,00

1º CARTÓRIO DE GO-ANÁPOLIS

06/08/2012

R$ 39.000,00

1º CARTÓRIO DE GO-ANÁPOLIS

06/08/2012

R$ 30.000,00

1º CARTÓRIO DE GO-ANÁPOLIS

17/07/2012

R$ 7.000,00

1º CARTÓRIO DE GO-ANÁPOLIS

05/07/2012

R$ 1.770,00

 

LAWSUITS:

 

 

 

DATE:

COURT OF LAW:

 

4

STATE LAWSUITS

24/08/12

VARA DE SP-CAMPINAS

 

 

FINANCIAL INFORMATION

 

GENERAL BALANCE SHEETS AS OF 31/12/2010, 31/12/2009 AND 31/12/2008.

( FIGURES ARE IN THOUSANDS OF REAIS ).

 

ASSETS

 

 

 

CURRENT:

31/12/2010

31/12/2009

31/12/2008

 

 

 

 

CASH AND BANKS

3.952

3.055

462

INVESTMENTS

2.088

1.681

1.160

CLIENTS

16.998

14.707

17.255

INVENTORY

14.381

11.053

18.719

 

----------------

----------------

----------------

TOTAL CURRENT ASSETS

37.419

30.496

37.596

 

LONG-TERM RECEIVABLES:

 

 

 

 

 

 

 

RECOVERABLE TAXES

296

47

279

OTHER CREDITS

4.873

1.057

77

 

----------------

----------------

----------------

TOTAL LONG-TERM RECEIVABLES

5.169

1.104

356

 

FIXED ASSETS:

 

 

 

 

 

 

 

FIXED ASSETS

11.637

10.486

9.974

 

----------------

----------------

----------------

TOTAL FIXED ASSETS

11.637

10.486

9.974

 

================

================

================

TOTAL ASSETS

54.225

42.086

47.926

 

LIABILITIES:

 

 

 

CURRENT:

31/12/2010

31/12/2009

31/12/2008

 

 

 

 

SUPPLIERS

11.000

8.095

11.324

LOANS AND FINANCING

17.237

12.539

19.357

TAXES & CONTRIBUTIONS

2.146

1.487

1.302

 

----------------

----------------

----------------

TOTAL CURRENT LIABILITIES

30.383

22.121

31.983

 

LONG TERM LIABILITIES:

 

 

 

 

 

 

 

TAXES AND CONTRIBUTIONS

14.822

13.912

11.460

INSTALLMENTS TAXES PAYABLE

609

728

1.043

 

----------------

----------------

----------------

TOTAL LONG TERM LIABILITIES

15.431

14.640

12.503

 

NET EQUITY:

 

 

 

 

 

 

 

SHARE CAPITAL

1.200

1.200

1.200

ACCRUED PROFIT (LOSS)

4.125

2.240

1.860

PROFIT SHARING

-3.990

-2.175

-1.839

PROFIT (LOSS) OF PERIOD

7.076

4.060

2.219

 

----------------

----------------

----------------

TOTAL NET EQUITY

8.411

5.325

3.440

 

================

================

================

TOTAL LIABILITIES

54.225

42.086

47.926

 

PROFIT AND LOSS ACCOUNTS AS OF 31/12/2010, 31/12/2009 AND 31/12/2008.

( FIGURES ARE IN THOUSANDS OF REAIS ).

 

 

31/12/2010

31/12/2009

31/12/2008

 

 

 

 

GROSS SALES

124.029

115.124

99.156

(-) TAXES ON SALES

18.565

17.122

15.097

 

----------------

----------------

----------------

NET SALES

105.464

98.002

84.059

(-) COST OF SOLD GOODS

68.802

66.001

56.280

 

----------------

----------------

----------------

GROSS PROFIT

36.662

32.001

27.779

OPERATING REVENUE (EXPENSE)

-24.494

-22.277

-20.257

FINANCIAL REVENUE(EXPENSE)

-5.460

-4.705

-5.577

 

----------------

----------------

----------------

OPERATIONAL PROFIT (LOSS)

6.708

5.019

1.945

NON-OPERATING RESULT

4.006

1.144

1.395

CONTRIBUTION/INCOME TAX

-3.638

-2.103

-1.120

 

----------------

----------------

----------------

NET PROFIT (LOSS)

7.076

4.060

2.220

 

 

RATIOS:

31/12/2010

31/12/2009

31/12/2008

 

QUICK RATIO

,76

 

,88

 

,59

 

CURRENT RATIO

1,23

 

1,38

 

1,18

 

ACCOUNTS RECEIVABLE TURNOVER

6,20

TIMES

6,66

TIMES

4,87

TIMES

DAYS' SALES IN RECEIVABLES

58,02

DAYS

54,02

DAYS

73,90

DAYS

INVENTORY TURNOVER

4,78

TIMES

5,97

TIMES

3,01

TIMES

ACCOUNTS PAYABLE PERIOD

57,56

DAYS

44,15

DAYS

72,44

DAYS

RETURN ON ASSETS

1,94

TIMES

2,33

TIMES

1,75

TIMES

SALES TURNOVER ON NET EQUITY

12,54

TIMES

18,40

TIMES

24,44

TIMES

NET WORTH TIE-UP

1,38

 

1,97

 

2,90

 

INDEBTEDNESS

5,45

 

6,90

 

12,93

 

EQUITY RATIO

15,51

%

12,65

%

7,18

%

WORKING CAPITAL RATIO

23,16

%

37,86

%

17,55

%

GENERAL SOLVENCY

1,18

 

1,14

 

1,08

 

RETURN ON NET EQUITY

84,13

%

76,24

%

64,53

%

RETURN ON SALES (PROFIT MARGIN)

6,71

%

4,14

%

2,64

%

GROSS PROFIT MARGIN

34,76

%

32,65

%

33,05

%

OPERATIONAL RESULT

6,36

%

5,12

%

2,31

%

SALES TURNOVER ON LIABILITIES

3,47

TIMES

4,43

TIMES

2,63

TIMES

FOREIGN CURRENCY ON ASSETS

 

 

 

 

 

 

FOREIGN CURRENCY ON LIABILITIES

 

 

 

 

 

 

 

EXCHANGE RATE:

 

 

US$ 1,00 = R$ 2,03

 - OFFICIAL RATE ON 30/10/2012

US$ 1,00 = R$ 1,66

 - OFFICIAL RATE ON 31/12/2010

US$ 1,00 = R$ 1,74

 - OFFICIAL RATE ON 31/12/2009

US$ 1,00 = R$ 2,33

 - OFFICIAL RATE ON 31/12/2008

 

COMMENTS ON THE FINANCIAL INFORMATION:

 

FOLLOWS ATTACHED WORKSHEET WITH MAIN FINANCIAL RATIOS.

 

THE FIGURES AVAILABLE SHOW A SATISFACTORY FINANCIAL STANDING. THE LEVEL OF INDEBTEDNESS IS VERY HIGH AND MAINLY IS COMPRISED BY TRADE AND FINANCIAL DEBTS BUT IT HAS GOOD CURRENT RATIO AND POSITIVE WORKING CAPITAL, CONSIDERED SUFFICIENT TO COVER THE SHORT TERM DEBTS. IN ADDITION, IT SHOWS GROWING SALES AND POSITIVE RESULTS.

 

REAL ESTATE:

 

   THE PARTNERS OWN REAL ESTATE VALUED AT R$ 940.000,00

 

DETAIL OF OWNED REAL ESTATE:

 

TYPE:

OTHERS

TOTAL AREA:

9.600 SQ MTS

VALUE:

R$ 6.000.000,00

ADDRESS:

PRIMÁRIA 5-D, QUADRA 10, MÓDULO 01, DAIA, ANÁPOLIS/GO

REMARKS:

BUILT UP AREA: 2.650 SQ MTS

 

VEHICLES:

 

   OWNED VEHICLES ARE VALUED AT R$ 34.195,59

 

MACHINES:

 

   OWNED MACHINES AND EQUIPMENTS ARE VALUED AT R$ 78.807,05

 

 

INSURANCE

 

SUBJECT IS ENGAGED IN THE WHOLESALE OF PHARMACEUTICALS, MEDICAL, COSMETIC AND CHEMICAL PRODUCTS AS WELL AS REAGENTS AND HEMO-DERIVATIVES.

 

 

BANKING REFERENCES

 

 

BRANCH/PHONE:

CITY:

BANCO DO BRASIL S/A

21 3150-3003

RIO DE JANEIRO/RJ

BANCO ITAU S/A

21 2544-2568

RIO DE JANEIRO/RJ

BANCO SAFRA S/A

21 2131-2300

RIO DE JANEIRO/RJ

 

REMARKS: IN BRAZIL THE BANKS ARE PROHIBITED BY LAW TO PROVIDE INFORMATION OR ANY KIND OF COMMENTS ABOUT THEIR CLIENTS. DUE TO THIS LAW PROHIBITION WE ARE UNABLE TO PROVIDE ANY BANKING DETAILS.

 

ACCORDING TO THE CENTRAL BANK OF BRAZIL OFFICIAL REPORT, THE COMPANY HAS NO RETURNED CHECKS UP TO DATE. (IN THE TERMS OF "CIRCULAR 1682 BRAZILIAN CENTRAL BANK").

 

 

ACTIVITIES COMMENTS

 

SUBJECT IS ENGAGED IN THE WHOLESALE OF PHARMACEUTICALS, MEDICAL, COSMETIC AND CHEMICAL PRODUCTS AS WELL AS REAGENTS AND HEMO-DERIVATIVES.

 

IMPORT AND EXPORT:

 

   IMPORTS FROM:

CHINA, INDIA, GERMANY, ITALY, SWITZERLAND AND SPAIN.

 

   EXPORTS TO:

SWITZERLAND.

 

MAIN CLIENTS:

 

 

 

 

 

DOMESTIC CLIENTS:

CITY:

 

BELFAR LTDA

BELO HORIZONTE/MG

 

BULLA FARMA MANIPULAÇÃO LTDA

PORTO ALEGRE/RS

 

CIMED INDÚSTRIA DE MEDICAMENTOS LTDA

SÃO PAULO/SP

 

DROGADERMA LTDA

SÃO PAULO/SP

 

ELI E SU PROD. FARMACÊUTICOS LTDA

GOIÂNIA/GO

 

FARMACE IND. QUIM. FARMACÊUTICA CEARENSE LTDA

BARBALHA/CE

 

FARMACIA BELLAFARMA LTDA

CAXIAS DO SUL/RS

 

FARMACIA CENTER FORMULA LTDA

SÃO PAULO/SP

 

FARMACIA CENTRAL DE NOVA IGUAÇU LTDA

NOVA IGUAÇU/RJ

 

FARMÁCIA NEOATIVA LTDA

BELO HORIZONTE/MG

 

FARMACOPA FARM. LTDA

RIO DE JANEIRO/RJ

 

FUNDAÇÃO PARA O REMEDIO POPULAR - FURP

SÃO PAULO/SP

 

GEOLAB IND. FARMACÊUTICA LTDA

ANÁPOLIS/GO

 

GREGHI & PAIVA LTDA

SANTOS/SP

 

GUEDES & PAIXÃO LTDA

MONTES CLAROS/MG

 

HIPOLABOR FARMACÊUTICA LTDA

BELO HORIZONTE/MG

 

INSTITUTO DE TECNOLOGIA EM FÁRMACOS

RIO DE JANEIRO/RJ

 

LABORATÓRIO FARMACÊUTICO DO EST. PERNAMBUCO - LAFEPE

RECIFE/PE

 

LABORATÓRIO GLOBO LTDA

SÃO JOSÉ DA LAPA/MG

 

LABORATÓRIO QUIMICO E FARMACÊUTICO DO EXÉRCITO - LQFEX

RIO DE JANEIRO/RJ

 

MEDQUIMICA IND. FARMACÊUTICA LTDA

JUIZ DE FORA/MG

 

NATURE DERME PHARMÁCIA MANIPULAÇÃO LTDA

BELO HORIZONTE/MG

 

OLIVEIRA & CAVALCANTI LTDA

BELO HORIZONTE/MG

 

PHARLAB IND. FARMACÊUTICA LTDA

LAGOA DA PRATA/MG

 

PHARMÁCIA COM. E MANIP. FARM. LTDA

GOIÂNIA/GO

 

TOKARSKI COMÉRCIO E INDÚSTRIA LTDA

GOIÂNIA/GO

 

UNIVERSIDADE FEDERAL DO R. G. DO NORTE - NUPLAN

NATAL/RN

 

YUKIKO ETO & CIA LTDA

SÃO JOSÉ DOS CAMPOS/SP

 

 

STAFF:

 

   NOT AVAILABLE

 

 

CONCEPT AND FULFILMENT

 

THE SUBJECT IS A WELL-ESTABLISHED COMPANY, OPERATING SINCE 1999. SO FAR IT HAS A TRADE HISTORY AFFECTED BY SOME DETRIMENTAL FILES.

 

THE COMPANY HAS TRADE RELATIONS WITH SEVERAL SUPPLIERS IN BRAZIL. THE SUPPLIERS EXTEND CREDIT FACILITIES TO THE SUBJECT IN TERMS AND AMOUNTS ACCORDING TO THE COMPANY'S NEEDS AND SO FAR NO PAYMENT PROBLEMS ARE NOTED.

 

THE LAWSUITS REPORTED ARE NOT RELATED WITH TRADE DEBTS. THEY ARE RELATED TO TAX DEBTS THAT FOR ANY REASON THE COMPANY HAS NOT YET PAID. NEVERTHELESS WE POINT OUT THAT THE SAID LAWSUITS DO NOT AFFECT THE COMPANY'S TRADE REPUTATION.

 

OUR INVESTIGATION THROUGH THE PUBLIC RECORDS SHOWED SOME DETRIMENTAL FILES REGISTERED AGAINST THE SUBJECT WHAT SHOWS IT HAS BEEN FAILING TO FULFILL SOME OF ITS TRADE COMMITMENTS. HOWEVER, THOSE DETRIMENTAL FILES ARE NOT CONSIDERED THAT RELEVANT IN RELATION TO THE COMPANY’S SCALE OF ACTIVITIES.

 

MAIN SUPPLIERS:

 

 

 

 

 

DOMESTIC SUPPLIERS:

CITY:

PHONE:

CARDINAL HEALTH BRASIL 402 LTDA

SOROCABA/SP

15 3235-3500

GETEC GUANABARA QUIMICA IND. S/A

SÃO GONÇALO/RJ

21 2602-2000

IMPACTA INDÚSTRIA E COMÉRCIO

CAJAMAR/SP

11 4447-7300

MERCK S/A

COTIA/SP

11 4616-5431

TRADBOR IND. COMERCIO LTDA

IPERÓ/SP

15 3739-4909

 

FOREIGN SUPPLIERS:

COUNTRY:

 

FERRO

GERMANY

 

GEMINI

INDIA

 

TIANJIN

CHINA

 

ZUHAI

CHINA

 

 

PAYMENT HISTORY:

 

01 SUPPLIER REPORTED PAYMENTS:

   TOTAL AMOUNT:  R$ 317,00

 

AMOUNT OF INVOICES PAID: 1

TOTAL OF PROMPT PAYMENTS: 100%

HIGHEST INVOICE: R$ 317,00

HIGHEST CREDIT: R$ 317,00

 

 

FINAL OPINION

 

THE SUBJECT HAS BEEN IN BUSINESS SINCE 1999. UP TO DATE IT HAS SOME ADVERSE INFORMATION BUT IT HAS HIGH SCALE OF ACTIVITIES.

 

BASED ON THE GENERAL INFORMATION AVAILABLE IT IS BELIEVED THAT GOOD TRADE RELATIONS MAY BE ESTABLISHED. CREDIT FACILITIES MAY BE EXTENDED WITHIN TERMS AND AMOUNTS ADEQUATE TO THE COMPANY'S FINANCIAL STRENGTH.

 

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.54.12

UK Pound

1

Rs.87.07

Euro

1

Rs.70.15

 

 

INFORMATION DETAILS

 

Report Prepared by :

PRL

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.